Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SUCNR1 | Q9BXA5 | 1/20 | 0.42 |
| ▸ | IDUA | P35475 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | FGF2 | P09038 | 1/20 | 0.31 |
| ▸ | AKT1 | P31749 | 1/20 | 0.31 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.30 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16077494 | 1.00 | SUCNR1 (0.42) | SUCNR1IDUAKDM4EALDH1A1FGF2 | |
| SCHEMBL8340283 | 0.84 | IDUA (0.47) | SUCNR1IDUAKDM4EALDH1A1FGF2 | |
| SCHEMBL13887430 | 0.84 | IDUA (0.47) | SUCNR1IDUAKDM4EALDH1A1FGF2 | |
| SCHEMBL13969565 | 0.84 | IDUA (0.47) | SUCNR1IDUAKDM4EALDH1A1FGF2 | |
| SCHEMBL15473351 | 0.84 | IDUA (0.47) | SUCNR1IDUAKDM4EALDH1A1FGF2 | |
| SCHEMBL23502390 | 0.84 | IDUA (0.47) | SUCNR1IDUAKDM4EALDH1A1FGF2 | |
| SCHEMBL19848245 | 0.84 | IDUA (0.47) | SUCNR1IDUAKDM4EALDH1A1FGF2 | |
| SCHEMBL17906334 | 0.84 | IDUA (0.47) | SUCNR1IDUAKDM4EALDH1A1FGF2 | |
| SCHEMBL20800901 | 0.84 | IDUA (0.47) | SUCNR1IDUAKDM4EALDH1A1FGF2 | |
| SCHEMBL13478556 | 0.84 | IDUA (0.47) | SUCNR1IDUAKDM4EALDH1A1FGF2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12017994-B2 | Compounds, compositions, and methods for selectively inhibiting β-glucuronidases and alleviating side effects associated with drug treatment induced diarrhea | SYMBERIX, INC. (US) | 2024-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12017994-B2 | Compounds, compositions, and methods for selectively inhibiting β-glucuronidases and alleviating side effects associated with drug treatment induced diarrhea | GUSB, SI, ENGASE | SUCNR1 924/4885IDUA 89/4885KDM4E 3671/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.